Estriol cream. The gentlest estrogen — and what it does for vaginal symptoms.

Estriol (E3) is one of the three human estrogens. It binds the estrogen receptor more weakly than estradiol, which makes it well-suited to local vaginal use where strong systemic effects are not the goal. Outside the U.S., estriol vaginal cream is a first-line treatment for genitourinary syndrome of menopause (GSM); inside the U.S., it is available primarily through compounding pharmacies because no estriol product is FDA-approved.

What estriol is and how it differs from estradiol

The body makes three estrogens: estradiol (E2, the strongest, dominant in reproductive years), estrone (E1, the post-menopause backup), and estriol (E3, dominant only in pregnancy). Estriol binds the estrogen receptor with roughly one-tenth the affinity of estradiol. That is a feature, not a bug — for vaginal symptoms you want a local effect with minimal systemic spillover.

What estriol cream treats

• Vaginal dryness
• Burning, itching, or irritation
• Painful sex (dyspareunia)
• Recurrent urinary tract infections in postmenopausal women
• Urinary urgency and frequency related to GSM

How it compares to other vaginal estrogen options

Safety, including for cancer survivors

Low-dose vaginal estrogen — including estriol — produces serum estrogen levels that remain in the postmenopausal range. The systemic exposure is roughly 1-2 orders of magnitude lower than oral or transdermal HRT. There is no observed increase in breast cancer recurrence with low-dose vaginal estrogen in observational data, and major societies (NAMS, ASCO) state it can be considered for breast cancer survivors with severe GSM after discussion with their oncologist — particularly when non-hormonal options have failed.

A black-box warning still appears on FDA-approved vaginal estrogen labels because it applies to systemic estrogen as a class. The clinical evidence for low-dose vaginal use does not support that warning, and major societies have asked for it to be revised.

How estriol cream is prescribed in the U.S.

Because no estriol product is FDA-approved domestically, U.S. clinicians who use estriol prescribe it through a 503A compounding pharmacy. Typical strengths are 0.5 mg/g or 1 mg/g cream, 0.5–1 g intravaginally daily for two weeks then 2-3 times per week. Some clinicians use estriol-only cream; others use combination "Bi-Est" creams (estradiol + estriol).

Kindr generally prescribes FDA-approved vaginal estradiol (Estrace, Imvexxy, Estring) as first-line because the evidence base, manufacturing standards, and insurance coverage are stronger. Compounded estriol can be appropriate when a patient has tolerability issues with FDA-approved options or strongly prefers it after a clinical discussion.

What to expect — timeline and side effects

Improvement in dryness and comfort typically begins within 2-3 weeks and reaches full effect by 8-12 weeks. Side effects are uncommon at low doses and include local irritation, slight discharge during the loading period, and occasional breast tenderness if the dose is higher than needed.

FAQ

Clinical sources

• NAMS — Genitourinary Syndrome of Menopause Position Statement
• NAMS / The Menopause Society — 2022 Hormone Therapy Position Statement
• ACOG — Hormone Therapy and Menopause
• U.S. FDA — Menopause and Hormones

Related guides

Explore more

• The complete Menopause Guide
• HRT guide cluster
• Free symptom checker
• Pricing

Information on this page is for educational purposes only and is not a substitute for individualized medical advice. Prescription medications require clinical evaluation and provider approval. Individual results vary. This is not an emergency service — if you are experiencing a medical emergency, call 911.